No surprise: AbbVie turns cold shoulder to a messy rheumatoid arthritis partnership with Ablynx
AbbVie is punting yet another high-profile rheumatoid arthritis development partnership. The pharma outfit is taking a pass on Ablynx’s Phase III-ready drug vobarilizumab and shrugging off its $175 million upfront buy-in.
The decision will come as no surprise to any careful observer of RA. The anti-IL-6R recently failed to pass muster in a Phase IIb trial, despite Ablynx’s best efforts to get analysts to look past the failure on the primary endpoint and on to more upbeat results in the study. And AbbVie already has an in-house rival that it’s been much more pumped about.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.